Xenikos is developing a novel therapy that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos’ mission is to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.

Introducing T-Guard®


T-Guard® is a medicine currently under development that safely and swiftly ‘resets’ the body’s immune system. It shows potential in the effective treatment of certain life-threatening immune conditions, such as transplant-related rejection, acute graft-versus-host disease (aGVHD), solid-organ rejection and several severe autoimmune diseases.
READ MORE
parallax background

A Patient’s Story


Jan Willem was diagnosed with a rare form of leukemia in 1994. His diagnosis was the start of a remarkable journey to recovery that demonstrates the potential of T-Guard® as a life-saving treatment option.


OUR INVESTORS

Medicxi5
RACAPITAL5
SanquinNieuwV2
OostNL2
SPX
NetherlandsEnterpriseAgency